JPMorgan downgraded Neumora Therapeutics (NMRA) to Underweight from Neutral without a price target The company’s Phase 3 KOASTAL-1 trial evaluating navacaprant as a monotherapy treatment in major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback